Physician profile
Patrick Deere
NPI 1477526275
$5,401.26
in general payments reported to CMS, 2019-2025
31 companies · $723 in 2025
The $723 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $625 · 2020: $515 · 2021: $833 · 2022: $831 · 2023: $772 · 2024: $1,103 · 2025: $723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,597.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $1,479.72 | 2019-2025 | Xeomin |
| Abbvie INC. | $1,007.41 | 2022-2025 | Botox, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals Lp | $890.73 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $465.59 | 2020-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $174.09 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $169.23 | 2019-2025 | Veozah |
| Pfizer INC. | $164.60 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $158.38 | 2019-2025 | Xifaxan |
| Esperion Therapeutics, INC. | $133.50 | 2021 | |
| Daiichi Sankyo INC. | $125.00 | 2019 | |
| Medtronic USA, INC. | $116.32 | 2019 | |
| Glaxosmithkline, LLC. | $58.06 | 2019-2023 | Shingrix |
| Otsuka America Pharmaceutical, INC. | $50.51 | 2021-2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $46.48 | 2020 | |
| Corium, LLC | $44.35 | 2023-2025 | Azstarys |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $28.96 | 2025 | Fanapt |
| Allergan, INC. | $28.55 | 2020 | |
| Idorsia Pharmaceuticals US INC | $24.91 | 2023 | Quviviq |
| Ironshore Pharmaceuticals INC. | $22.54 | 2023 | Jornay Pm |
| Biohaven Pharmaceutical Holding Company Ltd. | $22.01 | 2022 | |
| Axsome Therapeutics, INC. | $21.05 | 2025 | Auvelity |
| Roche Diagnostics Corporation | $20.85 | 2020 | |
| Sumitomo Pharma America, INC. | $19.38 | 2024 | Gemtesa |
| Hologic Sales and Service, LLC | $18.93 | 2020 | |
| Sanofi-Aventis U.S. LLC | $17.98 | 2022 | |
| Corcept Therapeutics | $17.39 | 2024 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $15.97 | 2020 | |
| Aytu Biopharma, INC. | $15.18 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.74 | 2020 | |
| Shield Therapeutics INC | $14.60 | 2024 | |
| Amgen INC. | $14.25 | 2024 | Prolia, Evenity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Deere listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.